NYSE - Nasdaq Real Time Price USD

Zimmer Biomet Holdings, Inc. (ZBH)

Compare
106.91 -1.49 (-1.37%)
At close: December 11 at 4:00:02 PM EST
106.65 -0.26 (-0.24%)
Pre-Market: 8:32:18 AM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
7,595,500.00
7,394,200.00
6,939,900.00
6,827,300.00
6,127,500.00
Cost of Revenue
2,143,300.00
2,083,800.00
2,019,500.00
1,960,400.00
1,824,300.00
Gross Profit
5,452,200.00
5,310,400.00
4,920,400.00
4,866,900.00
4,303,200.00
Operating Expense
3,926,600.00
3,859,100.00
3,728,300.00
3,861,500.00
3,598,500.00
Operating Income
1,525,600.00
1,451,300.00
1,192,100.00
1,005,400.00
704,700.00
Net Non Operating Interest Income Expense
-206,400.00
-201,200.00
-164,800.00
-208,400.00
-212,100.00
Other Income Expense
-287,200.00
-182,900.00
-623,800.00
-298,000.00
-597,800.00
Pretax Income
1,032,100.00
1,067,300.00
403,500.00
499,000.00
-105,200.00
Tax Provision
-52,700.00
42,200.00
112,300.00
53,500.00
-96,000.00
Net Income Common Stockholders
1,083,500.00
1,024,000.00
231,400.00
401,600.00
-138,900.00
Diluted NI Available to Com Stockholders
1,083,500.00
1,024,000.00
231,400.00
401,600.00
-138,900.00
Basic EPS
5.27
4.91
1.10
1.93
-0.67
Diluted EPS
5.24
4.88
1.10
1.91
-0.67
Basic Average Shares
205,250.00
208,700.00
209,600.00
208,600.00
207,000.00
Diluted Average Shares
206,025.00
209,700.00
210,300.00
210,400.00
207,000.00
Total Operating Income as Reported
1,250,900.00
1,277,700.00
696,300.00
860,300.00
83,100.00
Total Expenses
6,069,900.00
5,942,900.00
5,747,800.00
5,821,900.00
5,422,800.00
Net Income from Continuing & Discontinued Operation
1,083,500.00
1,024,000.00
231,400.00
401,600.00
-138,900.00
Normalized Income
1,300,434.00
1,190,656.00
647,671.80
722,008.60
443,068.00
Interest Expense
206,400.00
201,200.00
164,800.00
208,400.00
212,100.00
Net Interest Income
-206,400.00
-201,200.00
-164,800.00
-208,400.00
-212,100.00
EBIT
1,238,500.00
1,268,500.00
568,300.00
707,400.00
106,900.00
EBITDA
2,212,400.00
2,220,200.00
1,494,700.00
1,645,100.00
1,005,300.00
Reconciled Cost of Revenue
1,748,600.00
1,693,600.00
1,619,900.00
1,552,200.00
1,438,000.00
Reconciled Depreciation
973,900.00
951,700.00
926,400.00
937,700.00
898,400.00
Net Income from Continuing Operation Net Minority Interest
1,083,500.00
1,024,000.00
290,200.00
445,000.00
-10,700.00
Total Unusual Items Excluding Goodwill
-274,600.00
-173,600.00
-495,800.00
-310,200.00
-621,600.00
Total Unusual Items
-274,600.00
-173,600.00
-495,800.00
-310,200.00
-621,600.00
Normalized EBITDA
2,487,000.00
2,393,800.00
1,990,500.00
1,955,300.00
1,626,900.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-57,666.00
-6,944.00
-138,328.20
-33,191.40
-167,832.00
12/31/2020 - 7/25/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ZIMV ZimVie Inc.
14.28
+2.37%
 
SYK Stryker Corporation
376.16
-1.70%
 
MDT Medtronic plc
82.92
-0.79%
 
SNN Smith & Nephew plc
25.76
+0.31%
 
GMED Globus Medical, Inc.
82.94
+0.06%
 
CNMD CONMED Corporation
73.32
-1.90%
 
BSX Boston Scientific Corporation
90.56
+0.40%
 
STE STERIS plc
209.62
-2.15%
 
IART Integra LifeSciences Holdings Corporation
24.15
+0.58%
 
BIO Bio-Rad Laboratories, Inc.
341.51
+0.48%